A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naïve chronic hepatitis C patients in Taiwan.

摘要: Treatments with pegylated interferon/ribavirin (PEG-IFN/RBV) has been standard-of-care in patients chronic hepatitis C virus (HCV) (CHC) infection and reimbursed Taiwan. However, the actual cost-effectiveness remains unclear. We aimed to evaluate a real-world for CHC treated PEG-IFN/RBV by using clinical cohort linkage National Health Insurance Research Database of The total itemized medical-care expenses outpatient visits 117 treatment-naive two million sampling were collected. Four components costs assessed, including antiviral agents, nonantiviral laboratory testing consultation costs. cost per sustained virological response (SVR) achieved was calculated cost-effectiveness. average treatment naive Taiwanese $4620. With an overall SVR rate 78.6%, $5878. 52 Genotype 1 (G1) $5133, $4420 antivirals, $380 nonantivirals, $302 laboratory, $78 consultation, compared $4209, $3635, $317, $233, $56 65 2 (G2) patients. at 67.3% G1 87.7% G2 patients, significantly higher than those ($7627 vs. $4799, p = 0.001). In current study, we provided genotype-specific could enhance decision-making policy-makers coming era directly acting therapy.